moneyheap
ABT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Abbott Laboratories (ABT) stock moving?
ABT closed at $110.46 on Nov 10, about 7.8% above the Oct 22 close of $102.51 but 5.6% below the Nov 5 intraday high of $117.07. The rally was led by a cluster of positive cardiovascular trial readouts on Nov 2 (Amulet 360 one-year VERITAS data and the TECTONIC SonicForce 30-day results), which lifted shares 3.7% that day. The Nov 4 session (+5.6%, 12.7M shares, the highest volume in the window) marked the peak of the move. Since then the stock has fallen back to the $110 area on volume that has eased to about 7.4M shares, which suggests the rally is cooling rather than reversing. Supporting news flow is broad: BofA raised its target to $125 with a Buy rating, implying about 13% upside, and there are new approvals and partnerships (Health Canada mylife Loop expansion, the Novo Nordisk Plosbrio deal in Asia Pacific, and an FDA device clearance). The Oct 21 announcement to separate the roughly $8.5B Nutrition business by end 2027 is a longer-term structural change that could sharpen focus but also brings execution and timing uncertainty. The provided items do not include Q3 2026 figures, so the earnings base is not verified here. Near-term direction depends on whether the stock holds the $110 area after the post-trial pullback.
News behind the analysis
- BofA Analyst Raises Abbott Price Target to $125Bank of America analyst Travis Steed raised the Abbott price target to $125 and kept a Buy rating. That target is about 13% above the Nov 10 close of $110.46.
- Abbott Launches Panbio™ COVID-19/Flu A&B Self-Test in CanadaAbbott introduced its Panbio COVID-19/Flu A&B self-test in Canada for the respiratory illness season. This is a minor product launch with limited financial impact.
- Health Canada Approves Expanded Compatibility for mylife Loop with Abbott's FreeStyle Libre 3 Plus SensorHealth Canada approved expanded compatibility of the mylife Loop insulin delivery system with Abbott's FreeStyle Libre 3 Plus glucose sensor. The approval covers use during pregnancy in Canada.
- Abbott and Novo Nordisk Expand Partnership to Launch Plosbrio® in Asia PacificAbbott and Novo Nordisk will distribute and promote the semaglutide diabetes medication Plosbrio across several Asia Pacific countries. The deal widens Abbott's diabetes footprint in the region.
- Abbott Touts Favorable Outcomes In Cardiovascular Device TrialsAbbott reported positive trial results for its Amulet 360 left atrial appendage occluder and its SonicForce coronary IVL system at a conference. The results support its cardiovascular device pipeline.
- Abbott Announces Positive One-Year Data for Amulet 360™ DeviceOne-year VERITAS data for the next-generation Amulet 360 device showed high left atrial appendage closure rates and a low incidence of stroke. The data were released as a late-breaking result.
- Abbott Announces Positive 30-Day Results from TECTONIC Clinical Trial for SonicForce™ Coronary IVL SystemThe investigational SonicForce coronary intravascular lithotripsy system met its primary endpoints in the TECTONIC trial, with 0.3% 30-day target lesion failure and 97% procedural success in 335 patients. The device is not yet approved.
- Abbott Initiates Pivotal Trial for Cephea™ Mitral Heart Valve DeviceAbbott started the CROWN-MV pivotal trial of its investigational Cephea mitral valve system for symptomatic mitral valve disease. The trial is an early pipeline step with no near-term revenue.
- Abbott Receives FDA Approval For First And Only Device In The U.S. To Treat Leaks After Heart Valve Replacement Without Additional SurgeryThe FDA approved an Abbott device that treats leaks after heart valve replacement without additional surgery. It is described as the first and only such device in the U.S.
- Abbott Announces Intention to Separate Nutrition Business into Independent Public CompanyAbbott plans a tax-free spin-off of its Nutrition business, with about $8.5 billion in annual sales, with separation expected by end of 2027. Abbott will keep its devices, diagnostics and established medicines portfolio.
About Abbott Laboratories
Abbott Laboratories is a large, diversified healthcare company that sells medical devices, diagnostic tests, nutrition products (such as Similac and Ensure) and branded generic medicines in more than 160 countries. It is known for its FreeStyle Libre glucose monitors, its cancer-testing business expanded through the 2026 acquisition of Exact Sciences, and more than 50 straight years of dividend increases. It also plans to spin off its nutrition business in late 2027.
How it makes money
Abbott makes money by selling healthcare products in four main groups. Medical devices are the largest, at roughly 40%+ of sales; this includes diabetes care (FreeStyle Libre), heart rhythm, heart failure, structural heart and vascular devices. Diagnostics, about a quarter of sales, covers core lab, rapid and molecular tests, plus cancer screening (Cologuard) added through Exact Sciences. Nutrition (infant and adult) and established pharmaceuticals (branded generics in emerging markets) make up roughly 20% and 10–15% of sales. Total yearly revenue was about $44 billion in 2025, and it grew in 2026 after the Exact Sciences deal.
What usually moves ABT
- FreeStyle Libre glucose monitor growth
- Medical device trial results and product launches
- Diagnostics and cancer-screening demand after the Exact Sciences deal
- Nutrition spin-off and quarterly guidance updates
- Currency moves and pricing in emerging markets